Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 1/14/2009 First Published: 3/17/2006


1.		Phase I/II Study of Motexafin Gadolinium Given Concurrently With Temozolomide and Fractionated Radiotherapy in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme or Gliosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				RTOG-0513 NCT00305864

Last Modified: 5/9/2008 First Published: 8/3/2007


2.		Phase II Study of Concurrent and Adjuvant Temozolomide With Radiotherapy in Young Patients With Diffuse Pontine Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Diagnostic, Supportive care, Treatment				Active				2 to 21				Other				CCLG-CNS-2007-04 CNS 2007 04, EU-20746, EUDRACT-2007-001768-60, NCT00514397


3.		Ferumoxytol and Gadolinium Magnetic Resonance Imaging (MRI) at 3T and 7T in Patients With Malignant Brain Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Diagnostic				Active				18 to 75				Other				OHSU-2864 NIH, NINDS, 5 R01 NS053468 02, NCT00659126

First Published: 7/15/2008


4.		Phase II Pilot Study of Neoadjuvant Sunitinib Malate Followed by Cytoreductive Nephrectomy and Adjuvant Sunitinib Malate in Patients With Stage IV Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Diagnostic, Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				UPCC-10807 UPCC 10807, PFIZER-807184, NCT00717587

Last Modified: 1/5/2009 First Published: 8/12/2008


5.		Phase II Pilot Study of Motexafin Gadolinium Combined With High-Dose Methotrexate-Based Chemotherapy, Rituximab, and Whole-Brain Radiotherapy in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				NCI, Pharmaceutical / Industry				NU-05H7 NU 05H7, PCI-P-NU-05H7, NCT00734773

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute